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The aim of this study was to determine whether the allergy status and other characteristics of 
common cold patients modify the effects of zinc acetate lozenges.
METHODS
We had available individual patient data for three randomized placebo-controlled trials in which 
zinc acetate lozenges were administered to common cold patients. We used both one-stage and two-
stage meta-analysis to estimate the effects of zinc lozenges. 
RESULTS
The total number of common cold patients was 199, the majority being females. Eighty percent of 
them fell into the age range 20-50 years. One third of the patients had allergies. The one-stage meta-
analysis gave an overall estimate of 2.73 days (95% CI 1.8 to 3.3 days) shorter colds by zinc acetate
lozenge usage. The two-stage meta-analysis gave an estimate of 2.94 days (95% CI 2.1 to 3.8 days) 
reduction in common cold duration. These estimates are to be compared with the 7 day average 
duration of colds in the three trials. The effect of zinc lozenges was not modified by allergy status, 
smoking, baseline severity of the common cold, age, sex, or ethnic group.
CONCLUSION
Since the effects of zinc acetate lozenges were consistent between the compared subgroups, the 
overall estimates for effect seem applicable over a wide range of common cold patients. While the 
optimal composition of zinc lozenges and the best frequency of their administration should be 
further investigated, given the current evidence of efficacy, common cold patients may be 
encouraged to try zinc lozenges for treating their colds.
What is already known about this subject: 
- Randomized trials have shown that zinc acetate lozenges shorten the duration of common cold 
episodes.
- One study found that the effect of zinc acetate lozenges was greater for patients with allergies.
What this study adds: 
- The effect of zinc acetate lozenges is not modified by allergy, smoking, baseline common cold 
severity, age, sex, or ethnic group. 
- The mean effect of 3 day reduction in common cold duration with zinc acetate lozenges is 
clinically relevant and appears widely applicable.
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Introduction
Interest in zinc lozenges for treating the common cold arose when the cold symptoms of a 3-
year-old girl with leukemia disappeared soon after she dissolved a therapeutic zinc tablet in her 
mouth instead of swallowing it as instructed [1]. The benefit seemed to be obtained from slowly 
dissolving the tablet in her mouth, which suggested that zinc might have local effects in the 
pharyngeal region. This observation led the girl's father to conduct the first randomized placebo-
controlled trial on the effects of zinc lozenges on common cold patients. In that study, zinc 
gluconate lozenges shortened the duration of colds significantly [1].
Since then, a series of trials on zinc lozenges have been carried out but the results were variable 
[2-5]. The daily dosage of elemental zinc in the trials had a 7-fold variation, which explains much 
of the inconsistency in the study findings [2]. The composition of the lozenges also differed; some 
of them contained substances that bind zinc tightly, preventing the release of free zinc ions. The 
composition differences also explain divergent results [3-6].
A previous meta-analysis indicated that 5 low-dose trials of zinc lozenges (<75 mg/d zinc) 
uniformly produced no effect on the duration of colds. However, 3 high-dose (>75 mg/d) zinc 
acetate trials produced a 42% reduction in the duration of colds on average, and 5 high-dose zinc 
gluconate trials found a 20% reduction in cold duration on average [2]. Since acetate binds zinc ions
less strongly than gluconate, zinc acetate has been proposed as the best salt for lozenges [4,5]. 
Although dissolving lozenges in the oro-pharyngeal region leads to the highest zinc levels in that 
anatomical region, a recent meta-analysis found no evidence that zinc acetate lozenges have less 
effect on nasal symptoms compared with cold symptoms that originate in lower anatomical regions 
[7]. Other systematic reviews on zinc and the common cold have been published [8-10], but some 
of them had methodological problems [11-13], and a Cochrane review was recently withdrawn [14].
Petrus et al. [15] reported that common cold patients who had positive skin testing for allergies 
were more responsive to the zinc acetate lozenges than those who were negative for allergies, but 
that association has not been analyzed in later studies. The effect of zinc lozenges might also be 
modified by smoking which influences the respiratory system, and by the severity of the common 
cold which reflects different levels of pathologic changes caused by the respiratory viruses. The 
goal of the present individual patient data (IPD) meta-analysis was to determine whether the 
efficacy of high-dose zinc acetate lozenges varies by the allergy status, smoking, baseline common 
cold severity or by demographic characteristics.
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Methods
Selection of the trials
This meta-analysis was restricted to placebo-controlled trials on zinc acetate lozenges for 
patients with naturally acquired common cold infections, in which the elemental zinc dosage was 
>75 mg/d. We restricted the selection to high-dose trials, since previous analyses demonstrated the 
lack of effect of low doses of zinc, < 75 mg/day [2,4,5,10]. Previous searches of the literature 
[2,5,8-10] identified 3 trials that met our selection criteria [15-17]. These three trials are shown in 
Table 1 and further characteristics are shown in Supplement file 1. No additional zinc acetate 
lozenge trials were found by searching PubMed and Scopus using the free search terms “zinc” and 
“lozenge*” (June 16, 2016). The three datasets for this IPD meta-analysis were made available with
the cooperation and collaboration of the authors of the three trials and the lead author. We did not 
use a protocol for this meta-analysis.
Outcome
The outcome in this meta-analysis was the duration of colds. Petrus et al. (1998) [15] reported 
both the mean duration of common cold symptoms and the duration of the longest cold symptom. 
We used the latter as the outcome for this analysis, since it is consistent with the outcome definition 
in the two studies by Prasad et al. [16,17]. 
Statistical methods
In checking of the IPD for the three studies, we confirmed that the effects of zinc lozenges in the
IPD data were consistent with the published effects [15-17].
Pooling of the IPD was done by the one-stage and two-stage approaches. One-stage meta-
analysis indicates that the pooled effect estimates are calculated directly from the IPD. Two-stage 
meta-analysis indicates that the effect estimates of the individual studies are first calculated from 
the IPD; thereafter, those study level estimates are pooled by standard meta-analysis methods. In 
some cases, the one-stage meta-analysis has greater statistical power and sometimes the two 
approaches lead to different conclusions [18].
We used the lmer procedure of the lme4 statistical package of R [19] for the one-stage meta-
analysis. In the mixed models constructed with lmer, we used the study as the random variable for 
the zinc effect and also as an independent explanatory variable. The interaction between the zinc 
lozenge effect and each subgroup variable was calculated by first adding the zinc effect and the 
subgroup variable to the basic model, and thereafter adding their interaction term; the interaction 
between zinc and the subgroup variable was added as a random variable. The p-value for the 
interaction was calculated by using the likelihood ratio test. 
In the two-stage pooling, we first used the lm procedure [19] to calculate the mean effects and the
zinc-subgroup interactions separately in the three trials. Thereafter we pooled those effects by the 
metagen procedure of the meta package using the inverse-variance and random-effects options [19].
The p-value for the interaction was calculated from the z-value of the pooled interaction effect. We 
used the χ2 test and the I2 statistic to assess statistical heterogeneity among the three trials in the 
two-stage approach. A value of I2 greater than about 70% indicates a high level of heterogeneity 
[20]. 
We used the difference in the duration of colds in days as the main measure of the zinc effect. 
However, since the distributions of viruses differ over time and the operational outcome definitions 
vary between trials, variation between studies is to be expected. Since relative effect adjusts for 
variation in the common cold duration in the placebo groups, we also calculated the overall effect of
zinc in the percentage scale so that the duration of each placebo group was normalized to 100%. 
Thereby the difference between the zinc group and the placebo group directly gives the effect of 
zinc lozenges in percentages.
Our calculations are described in detail in Supplement file 2. Two-tailed p-values are used.
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Results 
Table 1 shows the distributions of the baseline variables of the three trials analyzed in this IPD 
meta-analysis. The trials had 199 common cold patients with the majority being females. Eighty 
percent of the common cold patients fell into the age range between 20 and 50 years. The majority 
was white, 23% were African Americans and 10% were of other ethnic origin. In the Petrus et al. 
study, all common cold patients were skin tested with 20 different allergy extracts including grasses,
trees, and cat and dog dander, and 46% of the patients tested positive for allergies [15], see details 
in Supplement file 1. In their two trials, Prasad et al. asked about allergies with a questionnaire and 
12% [16] and 20% [17] reported having allergies. Petrus et al. did not record information about 
smoking, whereas in the two studies by Prasad et al., a quarter of participants were smokers. All 
three studies were randomized, double-blind, placebo-controlled trials, and there were few drop-
outs. Further details of the methodology of the three trials are described in Supplement file 1.
Petrus et al. instructed patients to dissolve in their mouth 1 lozenge every 1½ hour while awake 
on the first day, and then 1 lozenge every 2 hours on the following days; lozenges dissolved in 
about 15 minutes [15]. Prasad et al. instructed patients to dissolve 1 lozenge in their mouth every 2 
to 3 hours while awake; their lozenges dissolved in about half an hour [5,16,17]. Elemental zinc 
dose varied between 80 and 92 mg/day in the three studies (Supplement file 1).
Table 2 shows the estimated effect of zinc acetate lozenges over all participants. The one-stage 
meta-analysis gives an estimate of a 2.73 day reduction in common cold duration and the two-stage 
meta-analysis gives an estimate of 2.94 days. These estimates are to be compared with the 7 day 
average duration of colds in the three trials (Table 2). The small difference between the two pooled 
estimates is explained by the substantially greater zinc effect and smaller SDs in the two small 
studies by Prasad et al. (N = 48 and N = 50), compared with the smaller effect and larger SD in the 
larger study by Petrus et al. (N = 101), see Table 2. The two-stage method gives a greater effect 
estimate for zinc lozenges since the total weight of the two studies by Prasad is 75%, although the 
number of participants is essentially equal with the Petrus et al. study [15], see forest plot in 
Supplement file 2.
The effectiveness of zinc acetate lozenges on the duration of colds on the relative scale is also 
shown in Table 2. One-stage IPD meta-analysis gave an estimate of 36% average reduction in 
common cold duration and the two-stage pooling gave an estimate of 40% average reduction in the 
duration of colds.
Table 3 shows the one-stage subgroup analyses of the zinc lozenge effects. The table shows the 
difference in the zinc lozenge effect between the complementary subgroups. The effect of zinc 
acetate lozenges was not modified by allergy, smoking, baseline severity of the cold, age, sex, or 
ethnic group. Age was analyzed as a continuous variable and no interaction with zinc effect was 
seen for that variable either. The two-stage approach gave similar results, see Supplement file 2. In 
the two-stage subgroup analysis, there was no heterogeneity in the interaction between the zinc 
effect and subgroups between the three trials. 
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Discussion  
The effect of zinc acetate lozenges on the common cold was not modified by allergy, smoking, 
baseline severity of the common cold, age, sex, or ethnic group (Table 3). Our IPD meta-analysis 
does not support the earlier indication that zinc lozenges might be more effective for participants 
who have allergies [15].
Since no subgroup differences were found in the effect of zinc acetate lozenges, the overall 
estimates calculated in Table 2 are the most useful estimates for common cold participants 
comparable to the patients included in these three trials. Thus, given an average common cold 
duration of approximately one week (Table 2), zinc acetate lozenges may shorten common cold 
duration by an average of 3 days over various population groups.
A previous meta-analysis of the same three trials calculated that zinc acetate lozenges shortened 
the duration of colds on average by 42% [2]. That calculation was based on fixed-effect pooling of 
the reported study-level estimates. The current one-stage and two-stage IPD meta-analyses give 
similar overall estimates, though the current study calculated random-effects models.
Our meta-analysis was restricted to three studies with zinc acetate lozenges. Since there is 
evidence that acetate binds zinc ions less strongly than gluconate, zinc acetate has been proposed as 
a more suitable salt for lozenges than zinc gluconate [4,5]. Nevertheless, three studies with high 
doses of zinc as zinc gluconate also reported a statistically significant 21% to 48% reduction in the 
duration of colds [1,21,22]; see meta-analysis in [2]. The data of those old zinc gluconate studies 
were no longer available and we restricted our subgroup analysis to the three zinc acetate trials for 
which we had the IPD available. 
Farr and Gwaltney [23] speculated that the apparent benefit of zinc gluconate lozenges reported 
by Eby (1984) [1] might have been explained by the bad taste of the lozenges. However, none of the
three zinc acetate lozenge trials included in our meta-analysis showed that bad taste was a problem. 
There was no substantial difference between the zinc and placebo groups in the occurrence of 
adverse effects and only a few dropouts occurred [15-17]. In the most recent trial [17], a few 
patients identified the type of lozenge that they were administered, but when the analysis was 
restricted to those who remained blinded at the end of the trial, the efficacy of zinc lozenges was 
comparable to the efficacy for all participants.
Zinc doses of 100 to 150 mg/day have been administered to certain patient groups for months 
with few adverse effects [2,24-27]. Thus, it is unlikely that a zinc dose of some 80 mg/day for one 
to two weeks, starting soon after the first common cold symptoms, might cause long-term adverse 
effects. If a patient considers that the taste of the zinc lozenge is bad, he or she can discontinue 
using the lozenges, whereas other common cold patients may continue its use. Although the 
evidence is strong that properly formulated zinc lozenges can shorten the duration of colds, it 
appears that the majority of zinc lozenges on the market have either doses of zinc which are too low
or contain substances that bind zinc, such as citric acid [5]. Therefore, the findings of this analysis 
should not be directly generalized to the wide variety of zinc lozenge formulations on the market.
In conclusion, our IPD meta-analysis found that the effect of zinc acetate lozenges on the 
duration of the common cold is not modified by allergy, smoking, baseline common cold severity, 
age, sex, or ethnic group. The calculated 3 day and 36% estimates for the reduction of common cold
duration are substantial effects and worth utilizing by common cold patients. The optimal 
composition of zinc lozenges and the best frequency of their administration should be further 
investigated. Nevertheless, given the current evidence of efficacy and the low rate of adverse 
effects, common cold patients may be encouraged to try zinc acetate lozenges for treating their 
colds.
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Supplement file 1: Description of the three studies included. See at the end of this manuscript.
Supplement file 2: Description of the statistical calculations. See at the end of this manuscript.
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Petrus (1998) [15] Prasad (2000) [16] Prasad (2008) [17]
All participants 199 101 48 50
Intervention
Zinc 102 52 25 25
Placebo 97 49 23 25
Age (y)
median 27.0 22.0 37.0 34.5
range 17-61 18-54 18-61 17-60
Sex
Male 82 47 18 17
Female 117 54 30 33
Allergy
No 137 55 42 40
Yes 62 46 6 10
Ethnic group
White 132 73 29 30
Black 47 15 16 16
Other 20 13 3 4
Smoker *
No 70 - 35 35
Yes 28 - 13 15
Severity score of the 
common cold at the 
baseline
Below median 102 57 23 22
Above median ** 97 44 25 28
* The Petrus study (1998) [15] did not collect data on smoking.
** The common cold severity above median was ≥8 points in the Petrus study (1998) [15], ≥11 
points in the Prasad study (2000) [16], and ≥8 points in the Prasad study (2008) [17], see 
Supplement file 1 for details.
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Table 2. Effect of high-dose zinc acetate lozenges on common cold duration among all participants 
in the three trials included
Duration of colds in the
placebo group 
(days) 




Effect of zinc on cold
duration in relative terms 
(in %)
Mean SD Estimate 
(in days)




Petrus 1998 [15] 7.1 3.9 -1.77 -3.1, -0.47 -25% -44%, -6.7%
Prasad 2000 [16] 8.1 1.8 -3.61 -4.6, -2.6 -45% -57%, -32%
Prasad 2008 [17] 7.1 1.3 -3.12 -3.8, -2.4 -44% -53%, -34%




7.3 -2.73 -3.3, -1.8 -36% -45%, -24%
Two-stage meta-
analysis
7.4 -2.94 -3.8, -2.1 -40% -50%, -30%
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Table 3. Difference in zinc acetate lozenge efficacy in subgroups: one-stage meta-analysis 








Age 199 -0.5 -1.1, +0.06 0.2
Allergy
No 137 ref.
Yes 62 -0.9 -2.0, +1.1 0.11
Sex
Male 82 ref.
Female 117 +0.5 -0.9, +2.1 0.17
Ethnic group **
White 132 ref.
Black 47 -0.1 -2.0, +1.4 0.2
Smoker
No 70 ref.
Yes 28 -0.2 -1.5, +1.0 0.3
Severity of the 
cold at the 
baseline
Below median 102 ref.
Above median 97 +0.4 -2.0, +2.8 0.13
* The minus sign in the estimate for the difference indicates that on average zinc lozenges have a 
greater effect in the second subgroup compared with the zinc lozenge effect in the reference group, 
or in older participants; however, the P-values indicate that all differences are due to chance 
variation. The modifying effect of age on the zinc lozenge effect is calculated for a 10 year interval.
** Ethnic groups other than white or African Americans were excluded from this comparison.
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This is additional material to a manuscript by Hemilä et al. (2016).
The tables in this document describes the selection of patients, the definition 
of outcomes, details of methods, and other essential characteristics of the three
included trials.
p. 1 Hemilä et al. (2016) Additional file 1
Petrus (1998) [15] http://www.currenttherapeuticres.com/article/S0011-393X%2898%2985058-3/abstract 
http://dx.doi.org/10.1016/S0011-393X(98)85058-3 
Methods Randomized, placebo-controlled, double-blind trial
Randomization “The bottles of the zinc lozenges and placebo were sent by the manufacturer and each bottle 
was identical except a sequential number. At registration, after qualifying for the study each 
patient was given a bottle of 180 lozenges. At the conclusion of the study, when the diaries 
were assembled, the code  for the bottles was sent by the manufacturer, and the patients 
were placed in the zinc or placebo category. Then the results were tabulated and the 
statistical analysis was undertaken” (Edward Petrus 24 March 2016).
Allocation concealment Patients and personnel did not know to which group the patients were allocated.
Blinding of patients and
personnel
Reported as double-blind, which implies that patients and personnel were blinded.
Blinding of outcome
assessment
Blinded “subjects were also informed that they were required to rate and record their 
symptoms in a diary ” (p. 598). “Subjects recorded their symptoms every day until their 
symptoms ceased (p. 598). 
Losses to follow-up 1 patient was lost to follow-up.
Patients Included in the analysis: 52 Zn and 49 placebo patients
47 M 54 F, mean age 26 yr (range 18 to 54 yr)
Patients were recruited from the campus of the University of Texas through 
posted announcements
Exclusions: serious illnesses, organ transplants, disability
“This study was conducted during July and August 1997, when pollen was at its 
lowest level” (p. 598). 
Common cold definition Presence of 2 or more of the following 11 symptoms: nasal drainage, nasal 
congestion, cough, fever, myalgia, headache, sore throat, scratchy throat, 
hoarseness, sneezing, malaise (p. 598).
Delay between cold onset
and treatment initiation
“97 of the 101 subjects started using zinc lozenges on the first day of enrollment 
in the study (4 started on day 2 of enrollment), but the dataset doesn’t contain 
any information on the length of time between onset of symptoms and start of 
zinc therapy” (Kenneth Lawson, email 11 Dec 2014).
Outcome definition Two outcomes were reported:
1) mean duration of all observed cold symptoms of the individual
2) duration of the longest-lasting common cold symptom.
Measurement of severity 
of the baseline cold
“Subjects were also informed that they were required to rate and record their 
symptoms in a diary at the same time each day. Symptoms [see the 11 symptoms
above] were graded as follows: 0 = absent; 1 = mild (symptom is present but not 
particularly a discomfort); 2 = moderate (symptom is clearly evident and a 
discomfort); or 3 = severe (symptom is a serious problem and clearly evident 
and a discomfort)” (p. 598).
Thus, the maximum of the scale was 33 points.
The recorded level of severity at the baseline varied from 2 to 23 points, with the
median at 7 points.
Intervention Zn acetate: one lozenge contained 9 mg Zn (p. 597).
Placebo lozenges contained sucrose octaacetate.
Patients were instructed to use 1 lozenge every 1½ hour while awake during day 
0, then 1 lozenge every 2 hour while awake on following days.
“averaged 9.9 lozenges per subject per day as long as symptoms persisted” 
(p. 599).
p. 2 Hemilä et al. (2016) Additional file 1
Daily Zn dose from the 
lozenges
89 mg/d = 9.9/d × 9 mg
Lozenges “The lozenges with zinc contained 9 mg of zinc in a 2.7 g dextrose base”
(p. 597).
“To achieve masking, sucrose octaacetate (0.169 mg) was used in the placebo, 
and both the placebo and zinc lozenges were peppermint flavored. A review of 
subjects’ diary entries revealed that 4 subjects noted a chalky taste, 4 
experienced a metallic aftertaste, and 3 complained of an upset stomach; none of
the subjects noted a bitter taste. Most subjects liked the peppermint flavor. ” 
(p. 599).
“The lozenges ... dissolved in the mouth in about 15 minutes” (p. 602).
“Lozenges dissolved in about 15 min ” (p. 31 on [8]).
“The Petrus and Prasad compressed lozenges were designed by the present 
author and were identical in composition. In addition to ZA, they contained 
directly compressible (agglomerated) dextrose as the tablet base, glycerol 
mono-stearate (2.5% tablet weight) as tablet lubricant, stevia for added 
sweetness and peppermint oil for flavor, with the composition compressed to 
near maximal hardness for slowest dissolution. Those ingredients were chosen 
specifically because they do not react with iZn” (p. 31 in [8]).
“Lozenges were small zinc acetate lozenges consisting of a dextrose tablet base, 
2.5% glycerol monostearate lubricant, stevia and peppermint oil on silica gel 
compressed with a force sufficient to allow them to dissolve in 15 min in the 
human mouth” (p. 485 in [9]).
Mean and SD of the 
common cold duration
Calculated from the IPD data set (the same as reported in 1998):
Zn: Mean duration of the longest-lasting symptom: 5.288 days (SD 2.569)
Placebo: Mean duration of the longest-lasting symptom: 7.061 days (SD 3.907).
Allergy testing “Because common colds and nasal allergies cause many of the same symptoms, 
skin tests were performed on each subject to determine whether allergies were 
present. All subjects were skin tested with 20 different allergy extracts, …The 
extracts included ragweed mix, burweed marsh elder, cedar elm, Bermuda grass, 
Johnson grass, perennial rye grass, mountain cedar (juniper), Virginia live oak, 
pecan, American elm, Alternaria alternata, Hormodenorum cladospo rioides, 
Helminthosporium sativum, cockroach mix (American and German), cat dander,
dog dander, dust mite mix, Western ragweed, a negative control (diluent), and a 
positive control (histamine). After a 15- to 30- minute waiting period, the results 
of the skin test were measured and recorded. Itching, swelling, or redness at the 
site of allergy extract application indicated a positive reaction to the allergen. 
Forty-six subjects (46%) tested positive for allergies, and 55 (54%) were 
negative” (pp. 597-598).
Adverse effects “Only 1 subject was lost to follow-up, and none of the remaining 101 
subjects discontinued because of side effects from the lozenges. ..
A review of subjects’ diary entries revealed that 4 subjects noted a chalky 
taste, 4 experienced a metallic aftertaste, and 3 complained of an upset 
stomach; none of the subjects noted a bitter taste. Most subjects liked the 
peppermint flavor” (p. 599). 
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Methods Randomized, placebo-controlled, double-blind trial
Randomization “A research consultant prepared the randomization code and the packages of medication. 
The packages were identical in appearance except for the randomization numbers. A 
research assistant who was blinded to treatment assignments distributed the study 
medication” (p. 246).
Allocation concealment Patients and personnel did not know to which group the patients were allocated.
Blinding of patients and
personnel




Blinded “participants were asked to complete a daily log documenting the severity of 
symptoms” (p. 246).
Losses to follow-up “Two persons in the placebo group dropped out on day 2. One of the two persons had a sore 
mouth, and the other developed an ear infection for which care was transferred to a 
physician outside of Detroit Medical Center” (Legend to Table 1, p. 247).
Patients Included in the analysis: 25 Zn and 23 placebo patients
18 M 30 F, mean age 37 yr (SD 11 yr).
Patients were students, staff, and employees at Wayne State University, 
Michigan, who were ≥18 yr. In general, subjects were recruited during fall and 
winter months.
Exclusions: Pregnancy, a known immunodeficiency disorder, chronic illnesses, 
and previous use of zinc lozenges.
Subjects with history of allergies were not excluded. 
Common cold definition Presence of 2 or more of the following 10 symptoms: cough, headache, 
hoarseness, muscle ache, nasal discharge, nasal congestion, scratchy throat, sore 
throat, sneezing, and fever (p. 246).
Delay between cold onset
and treatment initiation
Inclusion required that the cold had lasted for 24 hours or less.
Outcome definition “Resolution of cold symptoms was defined as the resolution of all symptoms 
(a total symptom score of 0) or the resolution of all but one mild symptom 
(a total symptom score of 1)” (p. 246).
Measurement of severity 
of the baseline cold
“Participants were asked to complete a daily log documenting the severity of  
symptoms [see the 10 symptoms above] and the medications taken throughout 
the duration of the cold. Every day, the participants graded each symptom as 0 
for none, 1 for mild, 2 for moderate, and 3 for severe. Total symptom scores 
were calculated by summing the scores ” (p. 246).
Thus, the maximum of the scale was 30 points.
The recorded level of severity at the baseline varied from 2 to 26 points, with the
median at 11 points.
Intervention Zn acetate: one lozenge contained 12.8 mg Zn (p. 245).
Placebo lozenges contained sucrose octaacetate.
patients were asked to dissolve 1 lozenge in their mouth every 2 to 3 hr while 
awake.
The reported mean number of lozenges used per day in the Zn group was 
6.2 (p. 249).
Daily Zn dose from the 
lozenges
80 mg/d = 6.2/d × 12.8 mg
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Lozenges “Each zinc lozenge consisted of 42.96 mg of zinc acetate dihydrate, 6.0 mg of 
peppermint oil, 16.0 mg of silica gel, 4.0 mg of stevia extract powder , 3.8 g of 
directly compressible dextrose, and 100 mg of glycerol monostearate. Each 
lozenge contained 12.8 mg of zinc. Each placebo lozenge contained 0.25 mg of 
sucrose octaacetate, 6.0 mg of peppermint oil, 16.0 mg of silica gel, 3.9 g of 
dextrose DC, and 100 mg of glycerol monostearate. The placebo and zinc 
lozenges were identical in weight (4 g), appearance, flavor, and texture” (p. 246).
“The Petrus and Prasad compressed lozenges were designed by the present 
author and were identical in composition. In addition to ZA, they contained 
directly compressible (agglomerated) dextrose as the tablet base, glycerol 
mono-sterate (2.5% tablet weight) as tablet lubricant, stevia for added sweetness 
and peppermint oil for flavor, with the composition compressed to near maximal 
hardness for slowest dissolution. Those ingredients were chosen specifically 
because they do not react with iZn [ionic zinc] . The slower dissolution of the 
4-g size lozenges was an advantage over the smaller lozenges in terms of 
efficacy” (p. 31 on [8]).
“Compressed with a force sufficient to allow them to dissolve in 30 min in the 
mouth” (p. 485 in [9]).
Mean and SD of the 
common cold duration
Calculated from the IPD data set (the same as reported in 2000):
Zn group: mean cold duration: 4.480 days (SD 1.636)
Placebo group: mean cold duration: 8.086 days (SD 1.807)
Maintenance of blinding “Comparability in taste between zinc and placebo was tested in healthy 
volunteers. Ten participants were given a zinc lozenge and 10 received a placebo
lozenge. One week later, the participants who received zinc were given placebo 
and those who received placebo were given zinc. At each visit, the participants 
filled out a questionnaire in which they were asked to guess whether they 
received a zinc or placebo lozenge. They had seven choices: certainly placebo, 
certainly zinc, do not know, possibly placebo, possibly zinc, probably placebo, 
and probably zinc. Volunteers who selected “certainly,” “probably,” or 
“possibly” and were correct about the type of lozenge they received were 
considered correct. We therefore categorized participants as “correct,” 
“incorrect,” or “do not know.” 
We assessed the adequacy of blinding among study participants by administering
the questionnaire used to assess comparability of taste in healthy volunteers. 
Participants filled out the questionnaire at the beginning and at the end of the 
trial” (p. 247).
“Of 20 participants who received zinc, 5% [n=1]correctly guessed that they were
receiving active therapy. Of 20 participants who received placebo, 10% [n=2] 
correctly guessed that they were receiving placebo. Therefore, participants did 
not correctly guess which type of lozenge they were receiving much better than 
by chance. In addition, at the beginning of the trial, 48% of zinc recipients and 
26% of placebo recipients correctly identified the lozenges (P > 0.2). At the end 
of the study, 56% of zinc recipients and 26% of placebo recipients correctly 
identified the lozenges (P = 0.09). None of these percentages exceeded 50%, 
indicating that blinding was adequate at the outset and was maintained 
throughout the study” (p. 247-248).
Adverse effects “Except for mouth dryness and constipation, no statistically significant side 
effects occurred in zinc recipients compared with placebo recipients” (p. 250).
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Prasad (2008) [17] http://jid.oxfordjournals.org/content/197/6/795 
http://dx.doi.org/10.1086/528803 
Methods Randomized, placebo-controlled, double-blind trial
Randomization “A research consultant prepared the randomization code and the packages of medication. 
The packages were identical in appearance except for the randomization numbers. A 
research assistant who was blinded to treatment assignments distributed the study 
medication ” (p. 796).
Allocation concealment Patients and personnel did not know to which group the patients were allocated.
Blinding of patients and
personnel
“A research assistant who was blinded to treatment assignments distributed the study 
medication ” (p. 796).
“The clinical assistant who collected all of the clinical information and remained in touch 
with the subjects who were recruited for the study remained completely blinded regarding 
the contents of the zinc and placebo pills” (Ananda Prasad 15 Dec 2014).
Blinding of outcome
assessment
Blinded patients completed daily logs.
Losses to follow-up No drop outs.
Patients Included in the analysis: 25 Zn and 25 placebo patients
16 M 34 F, mean age 35 yr (SD 14 yr)
Patients were students, staff, and employees at Wayne State University, 
Michigan, who were ≥18 yr
Exclusions: Pregnancy, any known immune deficiency disorder or chronic 
illness, and previous use of zinc lozenges.
Common cold definition Presence of 2 or more of the following 10 symptoms: cough, headache, 
hoarseness, muscle ache, nasal drainage, nasal congestion, scratchy throat, sore 
throat, sneezing, and fever (p. 796).
Delay between cold onset
and treatment initiation
Inclusion required that the cold had lasted for 24 hours or less.
Outcome definition “Resolution of cold symptoms was defined as the resolution of all symptoms 
(a total symptom score of 0) or the resolution of all but 1 mild symptom 
(a total symptom score of 1)” (p. 797).
Measurement of severity 
of the baseline cold
“Participants were asked to complete a daily log documenting the severity of 
symptoms [see the 10 symptoms above] ... the subjects graded each symptom as 
0 for none, 1 for mild, 2 for moderate, or 3 for severe. Total symptom scores 
were calculated by summing the scores of the 10 symptoms for each day” (p. 
796-797).
Thus, the maximum of the scale was 30 points.
The recorded level of severity at the baseline varied from 2 to 20 points, with the
median at 8 points.
Intervention Zn acetate: one lozenge contained 13.3 mg Zn (p. 796).
Placebo lozenges contained sucrose octaacetate.
patients were asked to dissolve 1 lozenge in their mouth every 2 to 3 hr while 
awake.
The reported mean number of lozenges used per day in the Zn group was 
6.9 (p. 799).
Calculation of the daily 
Zn dose from lozenges
92 mg/d = 6.9/d × 13.3 mg
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Lozenges “The lozenges were cherry oil–flavored Fast Dry zinc acetate lozenges, 
manufactured by F & F Foods (Chicago, IL). The active lozenges contained 13.3
mg of zinc as zinc acetate in a hard candy that contained 3.8 g of sucrose and 
corn syrup and that was prepared using the open-pot batch method, with the 
active ingredient added last. 100% of the zinc was available at physiologic pH 
7.4 in positively charged, ionic form. The placebo lozenges were of identical 
composition, except that they contained 0.25 mg of sucrose octaacetate rather 
than the active ingredient, zinc. There were no fats, metal chelators, or other zinc
ion– binding agents in either the active or placebo lozenges. The placebo and 
zinc lozenges were identical in weight, appearance, flavor, and texture and were 
supplied by George Eby” (p. 796).
Mean and SD of the 
common cold duration
Calculated from the IPD data set (the same as reported in 2008):
Zn group: mean cold duration: 4.00 days (SD 1.04)
Placebo group: mean cold duration: 7.12 days (SD 1.26)
Maintenance of blinding “Comparability in taste between zinc and placebo was tested in the participants 
at the beginning and the end of the trial. The participants filled out a 
questionnaire in which they were asked to guess whether they had received zinc 
or placebo lozenges. They had 5 choices: certainly placebo, certainly zinc, do not
know, probably placebo, and probably zinc. Subjects who selected certainly or 
probably and were correct about the type of lozenges they received were 
considered to be correct. We therefore categorized participants as correct, 
incorrect, or do not know” (p. 797).
“In the zinc group at the beginning of the study, only 1 subject identified the 
lozenges as certainly zinc, and 2 subjects identified them as probably zinc. Thus,
3 (12%) of 25 subjects in this group were correct. At the end of the study, 2 (8%)
were correct; 1 subject identified the lozenges as certainly zinc, and another 
subject identified them as probably zinc. 
In the placebo group at the beginning of the study, 1 subject said that the 
lozenges were certainly placebo, and another subject identified them as probably
placebo. Thus, 2 subjects (8%) in this group were correct. At the end of the 
study, none of the subjects identified the placebo lozenge correctly” (p. 799).
Adverse effects “Adverse effects of the zinc and placebo lozenges are compared in table 3. The 
zinc and placebo groups did not differ significantly in the incidences of any of 
the adverse effects, including diarrhea, constipation, sweet taste, sour taste, bitter
taste, aftertaste, dry mouth, mouth irritation, or bad taste. None of the subjects 
complained of either abdominal pain or vomiting” ( p. 799).
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Table S1. Normalization of the common cold duration to Placebo group = 100%
The values on the right hand side 
are used in in the calculation of 
the percentage effects of zinc 
acetate.
These values are calculated by 
dividing the figures on the left 
side by the mean common cold 
duration in the placebo group on 
the left side marked by yellow. 
Eg, Petrus (1998) zinc group:
5.29/7.06 = 0.7493 = 74.9%
This transformation leads to 
percentage scale so that all the 
differences between Zn and 
placebo groups are percentage 
effects.
Trial [ref]
Duration of colds 
(days)
Duration of colds 
(% of the placebo level)
Zn Placebo Zn Placebo
Mean SD Mean SD Mean SD Mean SD
Petrus 1998 [15] 5.29 2.57 7.06 3.91 74.9 36.4 100 55.3
Prasad 2000 [16] 4.48 1.64 8.09 1.81 55.4 20.2 100 22.3
Prasad 2008 [17] 4.99 1.04 7.12 1.27 56.2 14.6 100 17.8
Above table shows the transformation of the mean duration in the three studies to the percentage 
scale. 
In Table 2 of the paper, the calculation of zinc acetate lozenge effect is done using 
the absolute scale of days (left-hand side of the table) and 
the relative scale (% effect on duration; right-hand side of the above table).
On the absolute scale, the Petrus (1998) study found 
an 1.77 day reduction in common cold duration (= 5.29 – 7.06 days). 
On the percentage scale, the Petrus (1998) study found 
an 25.1% reduction in common cold duration (= 74.9% – 100% = 5.29/7.06 -1).
The relative scale has the benefit of adjusting for baseline variations between the placebo groups.
Nevertheless, the absolute duration of the colds was used in the IPD subgroup analyses.
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Table S2. Difference in zinc acetate lozenge efficacy in subgroups: Two-stage meta-analysis 








Age 199 -0.3 -0.7, +0.1 0.15
Allergy
No 137 ref.
Yes 62 -0.7 -2.0, +0.5 0.24
Sex
Male 81 ref.
Female 118 +0.3 -0.8, +1.4 0.6
Ethnic group **
White 133 ref.
Black 46 -0.04 -1.2, +1.1 0.9
Smoker
No 71 ref.
Yes 27 -0.2 -1.4, +1.0 0.7
Severity of the 
cold at the 
baseline
Below median 102 ref.
Above median 97 +0.3 -1.2, + 1.7 0.7
* The minus sign in the estimate for the difference indicates that on average zinc lozenges have a 
greater effect in the second subgroup compared with the zinc lozenge effect in the reference group, 
or in older participants; however, the P-values indicate that all differences are due to chance 
variation. The modifying effect of age on the zinc lozenge effect is calculated for a 10 year interval.
** Ethnic groups other than white or African Americans were excluded from this comparison.
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Table 2 analyses: One-stage pooling
Effect on common cold duration in days
> All <- lmer(Duration ~ 0+ Study + Zinc + (Zinc-1|Study))
> summary(All)
Linear mixed model fit by REML ['lmerMod']
Formula: Duration ~ 0 + Study + Zinc + (Zinc - 1 | Study)
REML criterion at convergence: 939
Random effects:
 Groups   Name Variance Std.Dev.
 Study    Zinc 0.605    0.778   
 Residual      6.577    2.564   
Number of obs: 199, groups:  Study, 3
Fixed effects:
            Estimate Std. Error t value
StudyPetrus    7.210      0.349   20.67
StudyP2000     7.870      0.486   16.19
StudyP2008     7.029      0.470   14.97
Zinc          -2.730      0.587   -4.65
Correlation of Fixed Effects:
           StdyPt SP2000 SP2008
StudyP2000  0.078              
StudyP2008  0.076  0.087       
Zinc       -0.261 -0.299 -0.291
> confint(All)
Computing profile confidence intervals ...
            2.5 % 97.5 %
.sig01       0.00   1.75
.sigma       2.33   2.83
StudyPetrus  6.84   8.09
StudyP2000   6.72   8.36
StudyP2008   6.04   7.63
Zinc        -3.27  -1.84
Effect on common cold duration in percentages
> PctAll <- lmer(DurPerc ~  0 + Study + Zinc + (Zinc-1|Study))
> summary(PctAll)
Linear mixed model fit by REML ['lmerMod']
Formula: DurPerc ~ 0 + Study + Zinc + (Zinc - 1 | Study)
REML criterion at convergence: 1967
Random effects:
 Groups   Name Variance Std.Dev.
 Study    Zinc   67      8.19   
 Residual      1284     35.83   
Number of obs: 199, groups:  Study, 3
Fixed effects:
            Estimate Std. Error t value
StudyPetrus   102.45       4.78   21.44
StudyP2000     97.29       6.56   14.83
StudyP2008     97.68       6.35   15.37
Zinc          -36.15       7.05   -5.13
Correlation of Fixed Effects:
           StdyPt SP2000 SP2008
StudyP2000  0.113              
StudyP2008  0.110  0.116       
Zinc       -0.328 -0.344 -0.336
> confint(PctAll)
Computing profile confidence intervals ...
            2.5 % 97.5 %
.sig01        0.0   18.8
.sigma       32.4   39.4
StudyPetrus  96.2  113.5
StudyP2000   83.4  106.1
StudyP2008   84.2  106.4
Zinc        -44.5  -24.6
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Table 2 analyses: Two-stage pooling: Effect on cold duration in days
Calculation of estimate and SD for the zinc lozenge effect:
> Petrus.lm    <- lm(Duration ~ Zinc, zincIPD[Study == "Petrus",])
> summary(Petrus.lm)
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)    7.061      0.470   15.04   <2e-16 ***
Zinc          -1.773      0.654   -2.71    0.008 ** 
Residual standard error: 3.29 on 99 degrees of freedom
Multiple R-squared:  0.069,     Adjusted R-squared:  0.0596 
F-statistic: 7.34 on 1 and 99 DF,  p-value: 0.00795
> P2000.lm <- lm(Duration ~ Zinc, zincIPD[Study == "P2000",])
> summary(P2000.lm)
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)    8.087      0.359   22.55  < 2e-16 ***
Zinc          -3.607      0.497   -7.26  3.7e-09 ***
Residual standard error: 1.72 on 46 degrees of freedom
Multiple R-squared:  0.534,     Adjusted R-squared:  0.524 
F-statistic: 52.7 on 1 and 46 DF,  p-value: 3.73e-09
> P2008.lm <- lm(Duration ~ Zinc, zincIPD[Study == "P2008",])
> summary(P2008.lm)
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)    7.120      0.232   30.68  < 2e-16 ***
Zinc          -3.120      0.328   -9.51  1.3e-12 ***
Residual standard error: 1.16 on 48 degrees of freedom
Multiple R-squared:  0.653,     Adjusted R-squared:  0.646 
F-statistic: 90.4 on 1 and 48 DF,  p-value: 1.3e-12
Pooling of the estimates calculated above:
> All.meta <- metagen(TE, seTE, studlab,data=subgroups[which(subgroups$Subgroup == "All"),],sm="MD")
> All.meta
               MD         95%-CI %W(fixed) %W(random)
Petrus 1998 -1.77 [-3.06; -0.49]      14.9       25.0
Prasad 2000 -3.61 [-4.58; -2.63]      25.9       32.6
Prasad 2008 -3.12 [-3.76; -2.48]      59.2       42.4
Number of studies combined: k=3
                        MD         95%-CI      z  p-value
Fixed effect model   -3.05 [-3.54; -2.55] -12.05 < 0.0001
Random effects model -2.94 [-3.81; -2.07]  -6.64 < 0.0001
Quantifying heterogeneity:
tau^2 = 0.3546; H = 1.6 [1; 2.99]; I^2 = 60.9% [0%; 88.8%]
Test of heterogeneity:
    Q d.f.  p-value
 5.11    2   0.0777
Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2
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Table 2 analyses: two-stage pooling: Effect on cold duration in days
Heterogeneity between the three studies is not statistically significant, with P = 0.08
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Table 2 analyses: Two-stage pooling: Effect on cold duration in  percentages  
Calculation of estimate and SD for the zinc lozenge effect:
> PercPetrus <- lm(DurPerc ~ Zinc, zincIPD[Study == "Petrus",])
> summary(PercPetrus)
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   100.00       6.65   15.04   <2e-16 ***
Zinc          -25.11       9.27   -2.71    0.008 ** 
Residual standard error: 46.5 on 99 degrees of freedom
Multiple R-squared:  0.069,     Adjusted R-squared:  0.0596 
F-statistic: 7.34 on 1 and 99 DF,  p-value: 0.00795
> PercP2000 <- lm(DurPerc ~ Zinc, zincIPD[Study == "P2000",])
> summary(PercP2000)
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   100.00       4.43   22.55  < 2e-16 ***
Zinc          -44.60       6.14   -7.26  3.7e-09 ***
Residual standard error: 21.3 on 46 degrees of freedom
Multiple R-squared:  0.534,     Adjusted R-squared:  0.524 
F-statistic: 52.7 on 1 and 46 DF,  p-value: 3.73e-09
> PercP2008 <- lm(DurPerc ~ Zinc, zincIPD[Study == "P2008",])
> summary(PercP2008)
Coefficients:
            Estimate Std. Error t value Pr(>|t|)    
(Intercept)   100.00       3.26   30.68  < 2e-16 ***
Zinc          -43.82       4.61   -9.51  1.3e-12 ***
Residual standard error: 16.3 on 48 degrees of freedom
Multiple R-squared:  0.653,     Adjusted R-squared:  0.646 
F-statistic: 90.4 on 1 and 48 DF,  p-value: 1.3e-12
Pooling of the estimates calculated above:
> AllPerc.meta <- metagen(TE, seTE, studlab,data=subgroups[which(subgroups$Subgroup == 
"AllPerc"),],sm="MD")
> AllPerc.meta
               MD          95%-CI %W(fixed) %W(random)
Petrus 1998 -25.1 [-43.3;  -6.94]      13.7       20.5
Prasad 2000 -44.6 [-56.6; -32.56]      31.1       34.5
Prasad 2008 -43.8 [-52.9; -34.78]      55.2       45.0
Number of studies combined: k=3
                        MD         95%-CI      z  p-value
Fixed effect model   -41.5 [-48.2; -34.8] -12.11 < 0.0001
Random effects model -40.2 [-49.9; -30.5]  -8.14 < 0.0001
Quantifying heterogeneity:
tau^2 = 33.1767; H = 1.35 [1; 2.48]; I^2 = 45% [0%; 83.7%]
Test of heterogeneity:
    Q d.f.  p-value
 3.64    2   0.1622
Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2
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Table 2 analyses: two-stage pooling: Effect on cold duration in  percentages  
Heterogeneity between the three studies is not statistically significant, with P = 0.16
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  Table 3 analyses: One-stage pooling: Interaction between zinc lozenge effect and allergy 
status
> AllerR2 <- lmer(Duration ~ Study + Study*Allergy + Zinc*Allergy + (Zinc-1|Study) +  
(Zinc:Allergy-1|Study) )
> summary(AllerR2)
Linear mixed model fit by REML ['lmerMod']
Formula: Duration ~ Study + Study * Allergy + Zinc * Allergy + (Zinc -  
    1 | Study) + (Zinc:Allergy - 1 | Study)
REML criterion at convergence: 930
Random effects:
 Groups   Name         Variance Std.Dev.
 Study    Zinc         9.14e-01 9.56e-01
 Study.1  Zinc:Allergy 5.24e-14 2.29e-07
 Residual              6.59e+00 2.57e+00
Number of obs: 199, groups:  Study, 3
Fixed effects:
                   Estimate Std. Error t value
(Intercept)           6.737      0.464   14.52
StudyP2000            0.942      0.672    1.40
StudyP2008            0.165      0.654    0.25
Allergy               0.968      0.664    1.46
Zinc                 -2.488      0.707   -3.52
StudyP2000:Allergy    0.339      1.246    0.27
StudyP2008:Allergy   -0.158      1.047   -0.15
Allergy:Zinc         -0.892      0.825   -1.08
Correlation of Fixed Effects:
            (Intr) StP2000 StP2008 Allrgy Zinc   SP2000: SP2008:
StudyP2000  -0.609                                              
StudyP2008  -0.627  0.428                                       
Allergy     -0.646  0.371   0.373                               
Zinc        -0.283 -0.039  -0.011   0.206                       
StdyP2000:A  0.242 -0.401  -0.167  -0.377  0.009                
StdyP2008:A  0.240 -0.164  -0.382  -0.348 -0.017  0.196         
Allergy:Znc  0.389 -0.152  -0.143  -0.635 -0.315  0.093  -0.048 
> confint(AllerR2)
Computing profile confidence intervals ...
                    2.5 % 97.5 %
.sig01              0.000   2.21
.sig02              0.000   1.66
.sigma              2.299   2.81
(Intercept)         6.345   7.97
StudyP2000         -0.863   2.13
StudyP2008         -1.479   0.60
Allergy            -0.561   1.97
Zinc               -3.253  -1.54
StudyP2000:Allergy -1.821   2.99
StudyP2008:Allergy -2.265   1.80
Allergy:Zinc       -1.955   1.13




Model 1: Duration ~ Study + Study * Allergy + Zinc + Allergy + (Zinc - 1 | Study) + 
(Zinc:Allergy - 1 | Study)
Model 2: Duration ~ Study + Study * Allergy + Zinc * Allergy + (Zinc - 1 | Study) + 
(Zinc:Allergy - 1 | Study)
  #Df LogLik Df Chisq Pr(>Chisq)
1  10   -466                    
2  11   -465  1  2.53       0.11
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Table S2 analyses: Two-stage pooling: Interaction between zinc and allergy: interaction 
estimates in the three studies
> AllPe    <- lm(Duration ~ Zinc*Allergy, zincIPD[Study == "Petrus",])
> summary(AllPe)
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept)     6.462      0.645   10.02   <2e-16 ***
Zinc           -1.082      0.888   -1.22     0.23    
Allergy         1.278      0.941    1.36     0.18    
Zinc:Allergy   -1.483      1.315   -1.13     0.26    
Residual standard error: 3.29 on 97 degrees of freedom
Multiple R-squared:  0.0868,    Adjusted R-squared:  0.0586 
F-statistic: 3.07 on 3 and 97 DF,  p-value: 0.0313
> AllP2000 <- lm(Duration ~ Zinc*Allergy, zincIPD[Study == "P2000",])
> summary(AllP2000)
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept)     7.947      0.397   20.03   <2e-16 ***
Zinc           -3.556      0.536   -6.63    4e-08 ***
Allergy         0.803      0.952    0.84     0.40    
Zinc:Allergy    0.306      1.591    0.19     0.85    
Residual standard error: 1.73 on 44 degrees of freedom
Multiple R-squared:  0.549,     Adjusted R-squared:  0.518 
F-statistic: 17.8 on 3 and 44 DF,  p-value: 1e-07
> AllP2008 <- lm(Duration ~ Zinc*Allergy, zincIPD[Study == "P2008",])
> summary(AllP2008)
Coefficients:
             Estimate Std. Error t value Pr(>|t|)    
(Intercept)     7.000      0.255   27.47   <2e-16 ***
Zinc           -3.000      0.370   -8.11    2e-10 ***
Allergy         0.750      0.637    1.18     0.25    
Zinc:Allergy   -0.750      0.840   -0.89     0.38    
Residual standard error: 1.17 on 46 degrees of freedom
Multiple R-squared:  0.663,     Adjusted R-squared:  0.641 
F-statistic: 30.2 on 3 and 46 DF,  p-value: 6.09e-11
p. 10 Hemilä et al. (2016) Supplementary file 2
Table S2 analyses: Two-stage pooling: pooling of the interaction estimates: allergy
Zinc effect and allergy
No interaction between zinc effect and allergy ( P = 0.24)
and no evidence of heterogeneity between studies (P = 0.7)
> ali <- metagen(TE, seTE, studlab,data=interactions[which(interactions$Subgroup == "Allergy"),],sm="MD")
> ali
                MD         95%-CI %W(fixed) %W(random)
Petrus 1998 -1.483 [-4.06; 1.094]      24.2       24.2
Prasad 2000  0.306 [-2.81; 3.425]      16.5       16.5
Prasad 2008 -0.750 [-2.40; 0.896]      59.3       59.3
Number of studies combined: k=3
                         MD         95%-CI     z  p-value
Fixed effect model   -0.753 [-2.02; 0.515] -1.16   0.2443
Random effects model -0.753 [-2.02; 0.515] -1.16   0.2443
Quantifying heterogeneity:
tau^2 = 0; H = 1 [1; 1.9]; I^2 = 0% [0%; 72.3%]
Test of heterogeneity:
    Q d.f.  p-value
 0.75    2   0.6869
Details on meta-analytical method:
- Inverse variance method
- DerSimonian-Laird estimator for tau^2
>
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Table S2 analyses: Two-stage pooling: pooling of the interaction estimates
Zinc effect and age
No interaction between zinc effect and age ( P = 0.15)
and no evidence of heterogeneity between studies (P = 0.7)
> agi <- metagen(TE, seTE, studlab,data=interactions[which(interactions$Subgroup == "Age10"),],sm="MD")
> agi
                MD          95%-CI %W(fixed) %W(random)
Petrus 1998 -0.243 [-1.719; 1.233]       7.4        7.4
Prasad 2000 -0.575 [-1.410; 0.260]      23.1       23.1
Prasad 2008 -0.204 [-0.686; 0.278]      69.5       69.5
Number of studies combined: k=3
                         MD          95%-CI     z  p-value
Fixed effect model   -0.293 [-0.694; 0.109] -1.43   0.1532
Random effects model -0.293 [-0.694; 0.109] -1.43   0.1532
Quantifying heterogeneity:
tau^2 = 0; H = 1 [1; 1.66]; I^2 = 0% [0%; 63.8%]
Test of heterogeneity:
    Q d.f.  p-value
 0.57    2   0.7502
>
Zinc effect and sex
No interaction between zinc effect and allergy ( P = 0.6)
and no evidence of heterogeneity between studies (P = 0.6)
> sei <- metagen(TE, seTE, studlab,data=interactions[which(interactions$Subgroup == "Sex"),],sm="MD")
> sei
                MD        95%-CI %W(fixed) %W(random)
Petrus 1998  1.374 [-1.21; 3.95]      17.0       17.0
Prasad 2000 -0.119 [-2.22; 1.98]      25.5       25.5
Prasad 2008  0.165 [-1.24; 1.57]      57.5       57.5
Number of studies combined: k=3
                        MD         95%-CI     z  p-value
Fixed effect model   0.298 [-0.765; 1.36] 0.549   0.5831
Random effects model 0.298 [-0.765; 1.36] 0.549   0.5831
Quantifying heterogeneity:
tau^2 = 0; H = 1 [1; 2.03]; I^2 = 0% [0%; 75.6%]
Test of heterogeneity:
    Q d.f.  p-value
 0.85    2   0.6525
>
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Table S2 analyses: Two-stage pooling: pooling of the interaction estimates
Zinc effect and ethnic origin
No interaction between zinc effect and ethnic origin ( P = 0.9)
and no evidence of heterogeneity between studies (P = 1.0)
> bli <- metagen(TE, seTE, studlab,data=interactions[which(interactions$Subgroup == "Black"),],sm="MD")
> bli
                 MD        95%-CI %W(fixed) %W(random)
Petrus 1998  0.2620 [-3.52; 4.04]      9.26       9.26
Prasad 2000 -0.0960 [-2.39; 2.20]     25.12      25.12
Prasad 2008 -0.0583 [-1.48; 1.36]     65.62      65.62
Number of studies combined: k=3
                          MD        95%-CI      z  p-value
Fixed effect model   -0.0381 [-1.19; 1.11] -0.065   0.9482
Random effects model -0.0381 [-1.19; 1.11] -0.065   0.9482
Quantifying heterogeneity:
tau^2 = 0; H = 1 [1; 1]; I^2 = 0% [0%; 0%]
Test of heterogeneity:
    Q d.f.  p-value
 0.03    2   0.9864
>
Zinc effect and smoking
No interaction between zinc effect and smoking ( P = 0.7)
and no evidence of heterogeneity between studies (P = 0.7)
> smi <- metagen(TE, seTE, studlab,data=interactions[which(interactions$Subgroup == "Smoker"),],sm="MD")
> smi
                 MD        95%-CI %W(fixed) %W(random)
Prasad 2000 -0.4833 [-2.76; 1.79]      28.6       28.6
Prasad 2008 -0.0775 [-1.52; 1.36]      71.4       71.4
Number of studies combined: k=2
                         MD        95%-CI      z  p-value
Fixed effect model   -0.194 [-1.41; 1.02] -0.312   0.7549
Random effects model -0.194 [-1.41; 1.02] -0.312   0.7549
Quantifying heterogeneity:
tau^2 = 0; H = 1; I^2 = 0%
Test of heterogeneity:
    Q d.f.  p-value
 0.09    1   0.7674
>
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Table S2 analyses: Two-stage pooling: pooling of the interaction estimates
Zinc effect and baseline common cold severity
No interaction between zinc effect and common cold severity ( P = 0.7)
and no evidence of heterogeneity between studies (P = 0.2)
> sevi <- metagen(TE, seTE, studlab,data=interactions[which(interactions$Subgroup == 
"SeveBin"),],sm="MD")
> sevi
                MD         95%-CI %W(fixed) %W(random)
Petrus 1998  2.196 [-0.372; 4.76]      15.5       22.4
Prasad 2000 -0.906 [-2.906; 1.09]      25.6       31.0
Prasad 2008  0.103 [-1.216; 1.42]      58.9       46.6
Number of studies combined: k=3
                        MD         95%-CI     z  p-value
Fixed effect model   0.170 [-0.842; 1.18] 0.329   0.7423
Random effects model 0.259 [-1.187; 1.70] 0.351   0.7257
Quantifying heterogeneity:
tau^2 = 0.7149; H = 1.33 [1; 2.42]; I^2 = 43.1% [0%; 82.9%]
Test of heterogeneity:
    Q d.f.  p-value
 3.51    2   0.1727
>
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The following three pages show the data set that was analyzed in the study
Most of the variables are evident.
The definition of severity is described in Additional file 1 and the continuous scale was transformed
to binary outcome “SeveBin” at the medians of the three studies.
Duration indicates the duration of common cold episodes
“DurPerc” is a transformed variable of duration so that:
all Petrus (1998) study duration values were divided by 7.0612 which is the placebo group 
mean common cold duration of that study,
all Prasad (2000) study duration values were divided by 8.0869 which is the placebo group 
mean common cold duration of that study,
all Prasad (2008) study duration values were divided by 7.12000 which is the placebo group 
mean common cold duration of that study,
“Study” variable indicates the studies, so that Petrus indicates the Petrus (1998) study [15], P2000 
indicates the Prasad (2000) study [16], and P2008 indicates the Prasad (2008) study [17].
“NA” indicates not available.
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zincIPD[,c(1:13)]
     ID Age Black Sex Allergy Smoker Severity SeveBin Zinc Duration DurPerc Cured  Study
1   103  21    NA   0       0     NA       10       1    1        8 113.295     1 Petrus
2   105  18     0   0       1     NA        2       0    1        3  42.486     1 Petrus
3   106  40     1   1       0     NA        7       0    1        4  56.647     1 Petrus
4   107  37     0   0       1     NA        7       0    1        7  99.133     1 Petrus
5   109  42     0   1       0     NA        4       0    1        6  84.971     1 Petrus
6   111  21     0   1       0     NA        7       0    1        4  56.647     1 Petrus
7   115  22     0   0       1     NA        7       0    1        7  99.133     1 Petrus
8   119  21     0   1       0     NA        6       0    1        5  70.809     1 Petrus
9   121  22     0   0       1     NA       12       1    1        7  99.133     1 Petrus
10  122  20     0   1       1     NA        8       1    1        6  84.971     1 Petrus
11  123  30     0   1       0     NA        2       0    1        2  28.324     1 Petrus
12  125  22     0   1       0     NA        7       0    1        8 113.295     1 Petrus
13  127  22     0   0       1     NA        5       0    1       12 169.942     1 Petrus
14  128  20     0   0       1     NA       14       1    1        4  56.647     1 Petrus
15  129  22     0   0       1     NA       12       1    1        7  99.133     1 Petrus
16  132  25     1   1       0     NA        5       0    1        4  56.647     1 Petrus
17  133  20     0   0       0     NA        4       0    1        2  28.324     1 Petrus
18  137  24     0   0       1     NA        8       1    1        5  70.809     1 Petrus
19  139  24     1   1       0     NA       10       1    1        5  70.809     1 Petrus
20  141  23     1   1       0     NA        5       0    1        4  56.647     1 Petrus
21  142  19    NA   0       0     NA        2       0    1        7  99.133     1 Petrus
22  144  47     0   1       0     NA        4       0    1       11 155.780     1 Petrus
23  145  35     1   1       1     NA       14       1    1        3  42.486     1 Petrus
24  146  20     0   0       1     NA        7       0    1        6  84.971     1 Petrus
25  147  20     0   0       1     NA        5       0    1        3  42.486     1 Petrus
26  148  22     0   1       0     NA        6       0    1        4  56.647     1 Petrus
27  151  43    NA   1       0     NA        2       0    1        4  56.647     1 Petrus
28  153  22     0   0       1     NA        3       0    1        7  99.133     1 Petrus
29  155  21     0   0       1     NA        8       1    1        2  28.324     1 Petrus
30  158  20     0   0       0     NA        6       0    1        3  42.486     1 Petrus
31  159  50     1   1       0     NA       12       1    1        6  84.971     1 Petrus
32  161  21     0   1       0     NA        8       1    1        8 113.295     1 Petrus
33  163  41     1   1       0     NA        9       1    1        6  84.971     1 Petrus
34  165  31     1   1       0     NA       12       1    1        6  84.971     1 Petrus
35  166  24     0   1       1     NA        7       0    1        3  42.486     1 Petrus
36  167  21     1   0       0     NA        6       0    1        3  42.486     1 Petrus
37  168  28    NA   0       1     NA        9       1    1        8 113.295     1 Petrus
38  170  19    NA   0       0     NA        9       1    1        3  42.486     1 Petrus
39  171  36     0   1       0     NA       12       1    1        9 127.457     1 Petrus
40  174  41    NA   1       1     NA        4       0    1        3  42.486     1 Petrus
41  178  21     0   0       1     NA        3       0    1        4  56.647     1 Petrus
42  180  39     0   0       0     NA        7       0    1        2  28.324     1 Petrus
43  181  20     0   1       0     NA        6       0    1        4  56.647     1 Petrus
44  184  20     0   1       0     NA        5       0    1        2  28.324     1 Petrus
45  185  29     0   1       1     NA        7       0    1        3  42.486     1 Petrus
46  191  23     0   0       1     NA        8       1    1        8 113.295     1 Petrus
47  192  20     0   1       0     NA       10       1    1       10 141.618     1 Petrus
48  194  23     0   1       0     NA       11       1    1        5  70.809     1 Petrus
49  196  21     0   1       0     NA        8       1    1       11 155.780     1 Petrus
50  198  22     0   0       1     NA        9       1    1        6  84.971     1 Petrus
51  199  21     0   0       1     NA        5       0    1        3  42.486     1 Petrus
52  201  50     0   0       1     NA        5       0    1        2  28.324     1 Petrus
53  101  23     1   1       1     NA       20       1    0        2  28.324     1 Petrus
54  102  54     0   0       1     NA       10       1    0        2  28.324     1 Petrus
55  104  18     0   0       0     NA       14       1    0        7  99.133     1 Petrus
56  108  18    NA   1       1     NA        6       0    0        7  99.133     1 Petrus
57  110  21     0   0       1     NA        6       0    0       14 198.266     1 Petrus
58  112  21     0   1       0     NA       15       1    0        5  70.809     1 Petrus
59  113  21     0   0       0     NA        5       0    0        4  56.647     1 Petrus
60  114  28     0   1       1     NA       10       1    0       11 155.780     1 Petrus
61  116  42     0   1       0     NA        7       0    0        8 113.295     1 Petrus
62  117  21     0   1       1     NA       10       1    0        3  42.486     1 Petrus
63  118  22     0   1       0     NA        9       1    0        7  99.133     1 Petrus
64  120  29     0   1       0     NA        9       1    0        4  56.647     1 Petrus
65  124  22     0   1       0     NA        4       0    0        4  56.647     1 Petrus
66  126  52     0   0       0     NA       10       1    0       13 184.104     1 Petrus
67  130  22    NA   0       0     NA       10       1    0        4  56.647     1 Petrus
68  131  24     0   0       0     NA        9       1    0        6  84.971     1 Petrus
69  134  21     1   1       1     NA        7       0    0       13 184.104     1 Petrus
70  135  36     1   0       1     NA        5       0    0        5  70.809     1 Petrus
71  136  50     0   1       0     NA        6       0    0        5  70.809     1 Petrus
72  138  23     0   0       1     NA        4       0    0        7  99.133     1 Petrus
73  140  30     0   1       1     NA       13       1    0       15 212.428     1 Petrus
74  143  37    NA   1       0     NA        4       0    0       15 212.428     1 Petrus
75  149  24     1   0       1     NA        7       0    0        8 113.295     1 Petrus
76  150  24     0   1       0     NA       12       1    0       11 155.780     1 Petrus
77  152  29     1   0       1     NA        3       0    0        4  56.647     1 Petrus
78  154  34    NA   1       0     NA       13       1    0        5  70.809     1 Petrus
79  156  24     0   0       0     NA        7       0    0        6  84.971     1 Petrus
80  157  25     0   1       0     NA       10       1    0        3  42.486     1 Petrus
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81  160  20     0   1       1     NA       14       1    0        4  56.647     1 Petrus
82  162  36    NA   1       1     NA        6       0    0       10 141.618     1 Petrus
83  164  23     1   1       1     NA        6       0    0        4  56.647     1 Petrus
84  169  19     0   1       0     NA        6       0    0        7  99.133     1 Petrus
85  172  27     0   0       1     NA       11       1    0       12 169.942     1 Petrus
86  173  31     0   1       1     NA       16       1    0        8 113.295     1 Petrus
87  175  18     0   0       1     NA        7       0    0       14 198.266     1 Petrus
88  176  22     0   0       0     NA        7       0    0        6  84.971     1 Petrus
89  177  27     0   0       0     NA        7       0    0        2  28.324     1 Petrus
90  179  32     0   0       0     NA        3       0    0        7  99.133     1 Petrus
91  182  21     0   1       1     NA        4       0    0        5  70.809     1 Petrus
92  183  21    NA   0       0     NA        4       0    0        6  84.971     1 Petrus
93  186  18     0   1       0     NA        5       0    0        3  42.486     1 Petrus
94  187  18     0   1       1     NA        2       0    0        4  56.647     1 Petrus
95  188  26     0   1       0     NA       18       1    0        4  56.647     1 Petrus
96  189  18     0   1       0     NA       17       1    0        5  70.809     1 Petrus
97  190  20     0   0       0     NA        5       0    0       15 212.428     1 Petrus
98  195  20     0   0       0     NA        7       0    0        6  84.971     1 Petrus
99  197  21     0   0       1     NA       23       1    0       15 212.428     1 Petrus
100 200  28     0   1       1     NA       13       1    0        5  70.809     1 Petrus
101 202  28    NA   0       1     NA        8       1    0        6  84.971     1 Petrus
102 801  22     0   1       0      0        9       1    1        6  84.270     1  P2008
103 802  32     1   1       0      1       12       1    1        4  56.180     1  P2008
104 803  49     1   0       0      1        8       1    1        2  28.090     1  P2008
105 804  37     1   1       0      1       14       1    1        3  42.135     1  P2008
106 805  49     1   0       1      1       17       1    1        5  70.225     1  P2008
107 806  29     0   1       0      0       20       1    1        4  56.180     1  P2008
108 807  26    NA   1       0      0        4       0    1        5  70.225     1  P2008
109 808  22     0   1       0      0        7       0    1        4  56.180     1  P2008
110 809  19     0   1       0      0        6       0    1        3  42.135     1  P2008
111 810  38     0   0       0      0        9       1    1        3  42.135     1  P2008
112 811  19     0   1       0      0        8       1    1        5  70.225     1  P2008
113 812  18     0   1       0      0        6       0    1        4  56.180     1  P2008
114 813  20     0   1       0      1        9       1    1        3  42.135     1  P2008
115 814  25     1   1       0      0       11       1    1        4  56.180     1  P2008
116 815  56     0   1       1      0        9       1    1        4  56.180     1  P2008
117 816  59     1   1       1      0        4       0    1        2  28.090     1  P2008
118 817  26     0   0       0      0        7       0    1        5  70.225     1  P2008
119 818  23     1   1       1      0        4       0    1        5  70.225     1  P2008
120 819  39    NA   0       0      0       11       1    1        4  56.180     1  P2008
121 820  18     0   1       0      0       14       1    1        5  70.225     1  P2008
122 821  50     1   1       0      0        5       0    1        4  56.180     1  P2008
123 822  46     0   1       1      0        2       0    1        3  42.135     1  P2008
124 823  50     0   1       1      0       10       1    1        5  70.225     1  P2008
125 824  31     0   0       0      0        5       0    1        3  42.135     1  P2008
126 825  60     0   0       0      1        8       1    1        5  70.225     1  P2008
127 826  27     0   1       1      0        8       1    0        7  98.315     1  P2008
128 827  29    NA   1       1      0       11       1    0        9 126.404     1  P2008
129 828  50     0   0       0      1        3       0    0        7  98.315     1  P2008
130 829  45     1   1       1      1       15       1    0        7  98.315     1  P2008
131 830  23     0   0       0      0       19       1    0        6  84.270     1  P2008
132 831  42     1   0       1      1        8       1    0        8 112.360     1  P2008
133 832  48     1   0       0      1        7       0    0        6  84.270     1  P2008
134 833  19     0   1       0      0       13       1    0        7  98.315     1  P2008
135 834  56     1   1       0      0        8       1    0        8 112.360     1  P2008
136 835  23     0   1       0      0        6       0    0        6  84.270     1  P2008
137 836  21     0   1       0      1        6       0    0        8 112.360     1  P2008
138 837  20     0   0       0      0        8       1    0       10 140.449     1  P2008
139 838  40     0   1       0      0        6       0    0        7  98.315     1  P2008
140 839  45     1   1       0      1        4       0    0        4  56.180     1  P2008
141 840  53     1   0       0      1        6       0    0        8 112.360     1  P2008
142 841  47     0   1       0      0        5       0    0        9 126.404     1  P2008
143 842  39    NA   0       0      0        8       1    0        7  98.315     1  P2008
144 843  50     0   1       0      0        4       0    0        7  98.315     1  P2008
145 844  19     0   0       0      0        9       1    0        5  70.225     1  P2008
146 845  51     1   0       0      0        4       0    0        7  98.315     1  P2008
147 846  46     0   1       0      1       14       1    0        7  98.315     1  P2008
148 847  17     0   1       0      0        3       0    0        8 112.360     1  P2008
149 848  20     0   1       0      0        5       0    0        7  98.315     1  P2008
150 849  22     1   1       0      0        9       1    0        6  84.270     1  P2008
151 850  45     0   0       0      1        8       1    0        7  98.315     1  P2008
152 301  42     0   1       0      0        5       0    1        4  49.462     1  P2000
153 302  27     0   1       1      1       13       1    1        3  37.097     1  P2000
154 303  59     0   1       0      0        7       0    1        3  37.097     1  P2000
155 304  43     1   1       0      1       14       1    1        7  86.559     1  P2000
156 305  23     0   1       0      0        9       0    1        5  61.828     1  P2000
157 306  40     1   0       0      1       13       1    1        5  61.828     1  P2000
158 307  61     0   1       0      0       14       1    1        6  74.194     1  P2000
159 308  25     1   1       0      0       12       1    1        3  37.097     1  P2000
160 309  41     0   1       0      0        3       0    1        3  37.097     1  P2000
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161 310  19     0   1       0      1        6       0    1        3  37.097     1  P2000
162 311  42     0   1       0      0       12       1    1        2  24.731     1  P2000
163 312  59     1   1       0      0       18       1    1        7  86.559     1  P2000
164 313  28     0   0       0      0        5       0    1        6  74.194     1  P2000
165 314  38     0   1       0      0       10       0    1        6  74.194     1  P2000
166 315  24     0   0       0      0        6       0    1        4  49.462     1  P2000
167 316  36     0   1       1      0       13       1    1        8  98.925     1  P2000
168 317  32     0   0       0      0        2       0    1        5  61.828     1  P2000
169 318  33     0   1       0      0       26       1    1        2  24.731     1  P2000
170 319  34     0   0       0      0       11       1    1        4  49.462     1  P2000
171 320  31    NA   1       0      1       14       1    1        5  61.828     1  P2000
172 321  35     1   1       0      0       12       1    1        3  37.097     1  P2000
173 322  25    NA   0       0      0       13       1    1        5  61.828     1  P2000
174 323  38     0   1       0      0       11       1    1        6  74.194     1  P2000
175 324  33     0   1       0      0       11       1    1        4  49.462     1  P2000
176 325  43     0   0       0      0       11       1    1        3  37.097     1  P2000
177 326  42     0   1       1      0        6       0    0       10 123.656     1  P2000
178 327  29     0   0       1      1        6       0    0        8  98.925     1  P2000
179 328  40     1   0       0      1       11       1    0        9 111.290     1  P2000
180 329  32     0   1       0      0       11       1    0        9 111.290     1  P2000
181 330  42     1   0       0      1        6       0    0        7  86.559     1  P2000
182 331  54     1   1       0      0       11       1    0       12 148.387     1  P2000
183 332  22     1   1       0      0       14       1    0        9 111.290     1  P2000
184 333  37     1   0       0      1       10       0    0        7  86.559     1  P2000
185 334  29     0   1       0      0        6       0    0        5  61.828     1  P2000
186 335  52     1   0       0      1       11       1    0       12 148.387     1  P2000
187 336  24     0   0       0      0       15       1    0        6  74.194     1  P2000
188 337  56     1   1       1      1       11       1    0        9 111.290     1  P2000
189 338  43     1   0       0      0        6       0    0        7  86.559     1  P2000
190 339  54     1   0       0      1        9       0    0        8  98.925     1  P2000
191 340  18     0   0       1      0        6       0    0        8  98.925     1  P2000
192 341  38     0   1       0      0        6       0    0        8  98.925     1  P2000
193 342  42     0   0       0      0        8       0    0        9 111.290     1  P2000
194 343  33     1   1       0      0       11       1    0        6  74.194     1  P2000
195 344  40     1   0       0      1        7       0    0        8  98.925     1  P2000
196 345  52     0   1       0      0        3       0    0        8  98.925     1  P2000
197 346  31    NA   1       0      0       15       1    0        7  86.559     1  P2000
198 347  23     0   1       0      0        6       0    0        5  61.828     1  P2000
199 348  37     0   1       0      0        7       0    0        9 111.290     1  P2000
> 
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